ZIM Laboratories Limited (BOM:541400)
India
· Delayed Price · Currency is INR | Market Cap | 4.54B |
| Revenue (ttm) | 3.78B |
| Net Income (ttm) | 69.83M |
| Shares Out | 53.55M |
| EPS (ttm) | 1.43 |
| PE Ratio | 59.04 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,392 |
| Average Volume | 3,853 |
| Open | 86.67 |
| Previous Close | 86.33 |
| Day's Range | 84.30 - 87.39 |
| 52-Week Range | 59.72 - 126.95 |
| Beta | 0.47 |
| RSI | 66.60 |
| Earnings Date | May 22, 2026 |
About ZIM Laboratories
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and ... [Read more]
Financial Performance
In fiscal year 2025, ZIM Laboratories's revenue was 3.79 billion, an increase of 3.16% compared to the previous year's 3.68 billion. Earnings were 121.65 million, a decrease of -29.46%.
Financial StatementsNews
Q2 2026 ZIM Laboratories Ltd Earnings Call Transcript
Q2 2026 ZIM Laboratories Ltd Earnings Call Transcript
Zim Laboratories Ltd (BOM:541400) Q3 2026 Earnings Call Highlights: Strong Export Growth Amid ...
Zim Laboratories Ltd (BOM:541400) Q3 2026 Earnings Call Highlights: Strong Export Growth Amid Regulatory Challenges
Q3 2026 ZIM Laboratories Ltd Earnings Call Transcript
Q3 2026 ZIM Laboratories Ltd Earnings Call Transcript
Why ZIM Laboratories has received CDSCO approval for its new Naproxen + Esomeprazole capsules
ZIM Laboratories Limited has announced that it has secured approval from the Central Drugs Standard Control Organization (CDSCO) for its...
ZIM Laboratories secures marketing authorization in Australia for urology drug combination
ZIM Laboratories Limited has received marketing authorization from Australia’s Therapeutic Goods Administration (TGA) for its fixed-dose combination capsules of Tamsulosin Hydrochloride and Dutasterid...
ZIM Laboratories shares in focus as company gets first marketing approval in Australia
ZIM Laboratories Limited announced that it has secured its first Marketing Authorization (MA) in Australia for its Central Nervous System (CNS) drug, Rizatriptan Benzoate Orally Disintegrating Films, ...